AAH PHARMACEUTICALS LIMITED

1. AAH PHARMACEUTICALS LIMITED 1987-04-28 → present
2. MAWSON & PROCTOR PHARMACEUTICALS LIMITED 1912-07-27 → 1987-04-28

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 101

Reporting scope

Standalone (parent only)

Auditor

BDO LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The Directors are required to assess whether adequate financial resources are available to continue to operate as a going concern for a period of not less than 12 months after the approval of these statutory financial statements... The Company has cash at bank and in hand of £29m, net current assets of £58m and net assets of £137m, demonstrating a strong financial position... The debt financing is sufficient to enable the Company and its subsidiaries to continue as a going concern at least 12 months after issuance of these financial statements. The ABL financial covenants require the AEL Group to maintain cash headroom of not less than £25 million at the close of each business day. The AEL Group Leverage/EBITDA ratio must not exceed 2.5. Therefore, the Directors concluded that they have a reasonable basis to support the going concern assertion for the financial statements.”

Group structure

1. AAH PHARMACEUTICALS LIMITED · parent
   1. Prima Brands Limited 100% · UK · Wholesale services
   2. Sangers (Northern Ireland) Limited 100% · UK · Wholesale Distribution
   3. Barclay Pharmaceuticals Limited 100% · UK · Wholesale distribution
   4. Pharmagen Limited 100% · UK · Wholesale services
   5. AAH Builders Supplies Limited 100% · UK · Dormant company

Significant events

• “On 28 May 2025, the parent company repaid the loan and the interest of £74,448,000 to the Company and the Company declared a dividend of £74,448,000 to the parent.”
• “Subsequent to the year end, in September 2025, the Aurelius Elephant Limited group refinanced its existing asset-backed loan ("ABL") facility. The revised facility, which has a minimum term of three years, increases the maximum borrowing capacity from £275 million to £350 million, secured against qualifying receivables of certain operating subsidiaries.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

6

last 12 months

Capital events

0

last 24 months

Officers appointed

2

last 12 months

Officers resigned

1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  -4%

  £3,085,011,000 → £2,962,474,000

• Cash

  +21.3%

  £24,298,000 → £29,473,000

• Net assets

  -76.5%

  £581,216,000 → £136,737,000

• Employees

  -1.6%

  2,831 → 2,787

• Operating profit

  +30.7%

  £39,714,000 → £51,904,000

• Profit before tax

  -16.2%

  £66,964,000 → £56,126,000

• Wages

  -3.1%

  £88,841,000 → £86,097,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. Periods don't have to be exactly 12 months apart — a long or short period (typical around incorporation or year-end changes) will distort the comparison. Lines a company doesn't report are omitted. About these numbers